Complications of Arteriovenous Fistula for Hemodialysis: An 8-Year Study

Fokou, Marcus; Teyang, Abel; Ashuntantang, Gloria; Kaze, François Folefack; Eyenga, Victor; Mefire, Alain Chichom; Angwafo, Fru

doi:10.1016/j.avsg.2011.09.014

Cited by 57 publications

(46 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Late causes for failure of AVFs include venous stenosis, thrombosis and acquired arterial lesions, such as aneurysms or stenoses. In the study by Fokou et al [62] , an overall frequency of complications of 16% is shown. These results show the potential for a low complication rate of AVF in a selected population.…”

Section: Permanent Vamentioning

confidence: 99%

Vascular access today

Pantelias

Grapsa²

2012

WJN

View full text Add to dashboard Cite

The number of patients with chronic kidney disease requiring renal replacement therapy has increased worldwide. The most common replacement therapy is hemodialysis (HD). Vascular access (VA) has a key role for successful treatment. Despite the advances that have taken place in the field of the HD procedure, few things have changed with regards to VA in recent years. Arteriovenous fistula (AVF), polytetrafluoroethylene graft and the cuffed double lumen silicone catheter are the most common used for VA. In the long term, a number of complications may present and more than one VA is needed during the HD life. The most common complications for all of VA types are thrombosis, bleeding and infection, the most common cause of morbidity in these patients. It has been estimated that VA dysfunction is responsible for 20% of all hospitalizations. The annual cost of placing and looking after dialysis VA in the United States exceeds 1 billion dollars per year. A good functional access is also vital in order to deliver adequate HD therapy. It seems that the native AVF that Brescia and Cimino described in 1966 still remains the first choice for VA. The native forearm AVFs have the longest survival and require the fewest interventions. For this reason, the forearm AVF is the first choice, followed by the upper-arm AVF, the arteriovenous graft and the cuffed central venous catheter is the final choice. In conclusion, VA remains the most important issue for patients on HD and despite the technical improvements, a number of problems and complications have to be resolved.

show abstract

Section: Permanent Vamentioning

confidence: 99%

Vascular access today

Pantelias

Grapsa²

2012

WJN

View full text Add to dashboard Cite

show abstract

“…2 However, shortand long-term AVF dysfunctions, including inadequate increase in blood flow volume (BFV) after surgery (nonmaturation), vein thrombotic occlusion, ischemic circulation in the distal arm and in the hand (steal syndrome), and massive increase in VA BFV with risk of cardiac failure, are among the major causes of morbidity and hospitalization in HD patients. 3,4 Indeed AVF primary patency at 2 years after surgery was recently estimated to be B50% [5][6][7] and even lower in the United States. 8,9 Prediction and prevention of VA dysfunction are still open clinical challenges, with more than 90,000 procedures/year performed in Europe for revision or reoperation.…”

mentioning

confidence: 99%

Validation of a patient-specific hemodynamic computational model for surgical planning of vascular access in hemodialysis patients

Caroli

Manini

Antiga³

et al. 2013

Kidney International

View full text Add to dashboard Cite

show abstract

“…14 In an 8-year analysis of complications in AVFs, no increase in complication rates was seen due to diabetes. 15,16 There has also been published work suggesting that vein diameter (and not diabetes) was a major significant independent predictor of maturation, which makes vessel mapping such a key point in patient pre-assessment. 17 Surgical experience is also thought to play an important role in the success of an AVF, with a 34% lower primary failure rate reported in fistulas created by experienced surgeons.…”

Section: Discussionmentioning

confidence: 99%

Diabetes should not dissuade arteriovenous fistula formation

et al. 2016

View full text Add to dashboard Cite

Background: Fistula maturation is a complex multifactorial process with the effect of diabetes on vessel augmentation during fistula formation remaining unclear. Variation in results has reflected in a range of clinical practice with regard to patient selection and fistula formation and so requires more study. The aim of our study was to compare outcomes of diabetic and non-diabetic patients undergoing formation of a new upper limb arteriovenous fistula (AVF) to assess whether diabetes has a prognostic effect on outcome. Methods: A retrospective cohort study analysing 339 patients looking at both radiocephalic and brachiocephalic fistula formation in diabetic and non-diabetic patients was designed, with the primary outcome being fistula failure and then time taken to mature. Results: No difference was found between diabetic and nondiabetic patients in terms of fistula failure or time to mature. Conclusions: With AVF remaining the best access for dialysis, diabetic patients should not be discouraged from being offered AVF formation as they have equivalent outcomes to non-diabetic patients.

show abstract

Complications of Arteriovenous Fistula for Hemodialysis: An 8-Year Study

Cited by 57 publications

References 18 publications

Vascular access today

Vascular access today

Validation of a patient-specific hemodynamic computational model for surgical planning of vascular access in hemodialysis patients

Diabetes should not dissuade arteriovenous fistula formation

Contact Info

Product

Resources

About